Views 979
Citations 0
Comment & Response
September 6, 2016

Methylphenidate for Attention-Deficit/Hyperactivity Disorder

Author Affiliations
  • 1Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany
  • 2Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany
  • 3Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Mannheim, Germany

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;316(9):994-995. doi:10.1001/jama.2016.10279

To the Editor In a JAMA Clinical Evidence Synopsis, Dr Storebø and colleagues1 summarized their previous Cochrane review2 on methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents. The original Cochrane review was flawed in both its methods and interpretation.3 We provide 2 examples.

First Page Preview View Large
First page PDF preview
First page PDF preview